Magenta Therapeutics, Inc. (MGTA) Stock Analysis
DELISTED 2023
What happened to Magenta Therapeutics, Inc. (MGTA) stock?
Magenta Therapeutics, Inc. (MGTA) no longer trades on public markets. It was delisted in September 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Magenta Therapeutics, Inc. (MGTA) trades at $0.6996. Magenta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative medicines for stem cell transplantation. Market cap: $42.4M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for MGTA: MGTA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MGTA against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
MGTA: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Magenta Therapeutics, Inc. (MGTA) Healthcare & Pipeline Overview
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company focusing on advancing stem cell transplantation through innovative medicines targeting blood cancers, genetic diseases, and autoimmune disorders. Their pipeline includes novel antibody drug conjugates and cell therapy programs, positioning them in the competitive biotechnology landscape.
What Is the Investment Thesis for MGTA?
Magenta Therapeutics operates in the high-risk, high-reward biotechnology sector, focusing on innovative stem cell transplant therapies. The company's pipeline, featuring MGTA-117 and CD45-antibody drug conjugate, represents potential value drivers if clinical trials are successful. A market capitalization of $42.4M reflects the speculative nature of the stock. The company's ongoing collaborations with AVROBIO and Beam Therapeutics could provide validation and additional revenue streams. However, the company's negative profit margin of -19892.3% highlights the significant financial risks. Successful advancement of clinical programs and strategic partnerships are key to driving shareholder value. The company's beta of 2.11 indicates high volatility relative to the market.
Based on FMP financials and quantitative analysis
MGTA Key Highlights
Market capitalization of $42.4M reflects the company's small size and speculative nature.
- Profit margin of -19892.3% indicates substantial losses and reliance on future clinical and commercial success.
- MGTA-117 is in Phase I/II clinical trial targeting acute myeloid leukemia and myelodysplastic syndromes.
- CD45-antibody drug conjugate is in investigational new drug application enabling studies for autoimmune diseases and hematology-oncology transplants.
- Collaboration agreements with AVROBIO and Beam Therapeutics provide potential for expanded therapeutic applications and revenue opportunities.
Who Are MGTA's Competitors?
MGTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | $107.79 | -1.04% | $9.36B | — |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MGTA's Key Strengths?
Innovative pipeline of drug candidates.
- Strategic collaborations with leading biotechnology companies.
- Expertise in stem cell biology and drug development.
- Focus on unmet medical needs in stem cell transplantation.
What Are MGTA's Weaknesses?
Clinical-stage company with no approved products.
- High cash burn and reliance on future funding.
- Significant regulatory and clinical trial risks.
- Limited commercial infrastructure.
What Could Drive MGTA Stock Higher?
Data readouts from MGTA-117 Phase I/II clinical trial.
- Initiation of clinical trials for CD45-antibody drug conjugate.
- Advancement of MGTA-145 through Phase II clinical trials.
- Progress in strategic collaborations with AVROBIO and Beam Therapeutics.
What Are the Key Risks for MGTA?
Financial-distress signal — its Altman Z-Score of 0.71 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-27.3%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures or delays.
- Regulatory setbacks or rejection of drug candidates.
- Competition from established pharmaceutical companies.
- Dependence on future funding and market conditions.
- Negative impacts from shifts in healthcare policy or reimbursement.
What Are the Growth Opportunities for MGTA?
- MGTA-117 Development: Advancing MGTA-117 through clinical trials represents a significant growth opportunity. Successful completion of Phase I/II trials and subsequent progression to later-stage trials could lead to regulatory approval and commercialization for treating acute myeloid leukemia and myelodysplastic syndromes. The market for these therapies is substantial, with a growing need for more effective treatments. Timeline: Ongoing clinical trials with potential data readouts in the next 1-2 years.
- CD45-Antibody Drug Conjugate: The development of the CD45-antibody drug conjugate offers a growth opportunity in autoimmune diseases and hematology-oncology transplants. Positive results from investigational new drug application enabling studies could pave the way for clinical trials and potential regulatory approval. The autoimmune disease market is large and growing, driven by an aging population and increasing prevalence of autoimmune disorders. Timeline: IND enabling studies ongoing, with potential clinical trials initiation in the next 2-3 years.
- MGTA-145 Clinical Trials: Advancing MGTA-145 through Phase II clinical trials for use in autologous and allogeneic transplants presents another growth avenue. Positive clinical data could lead to regulatory approval and commercialization, addressing the need for improved transplant outcomes. The market for stem cell transplants is expanding, driven by advancements in transplant techniques and increasing use of transplants for various diseases. Timeline: Ongoing Phase II clinical trials with potential data readouts in the next 1-2 years.
- E478 Cell Therapy Program: The E478 cell therapy program, focused on stem cell-based gene therapy and genome editing, represents a long-term growth opportunity. Successful development of this program could lead to innovative therapies for genetic diseases. The market for gene therapy is rapidly growing, driven by technological advancements and increasing clinical success. Timeline: Preclinical development ongoing, with potential clinical trials initiation in the next 3-5 years.
- Strategic Collaborations: Leveraging strategic collaborations with companies like AVROBIO and Beam Therapeutics provides opportunities for expanded therapeutic applications and revenue generation. These collaborations can accelerate the development and commercialization of Magenta's pipeline. The partnerships with AVROBIO for lysosomal storage disorders and Beam Therapeutics for sickle cell disease and beta-thalassemia could lead to significant milestones. Timeline: Ongoing collaborations with potential milestone payments and revenue sharing in the next 2-5 years.
What Are MGTA's Competitive Advantages?
- Proprietary drug candidates targeting stem cell transplantation.
- Strategic collaborations with leading biotechnology companies.
- Expertise in stem cell biology and drug development.
- Pipeline of innovative medicines addressing unmet medical needs.
What Does MGTA Do?
Magenta Therapeutics, Inc., founded in 2015 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company dedicated to revolutionizing stem cell transplantation. The company was initially known as HSCTCo Therapeutics, Inc. before rebranding to Magenta Therapeutics in February 2016, reflecting its focus on transforming hematopoietic stem cell transplantation. Magenta’s mission is to develop medicines that harness the curative potential of stem cell transplants to treat patients suffering from blood cancers, genetic diseases, and autoimmune disorders. Their pipeline includes several promising drug candidates, such as MGTA-117, an anti-CD117 antibody currently in Phase I/II clinical trials, designed to target hematopoietic stem cells and genetically mutated stem cells responsible for conditions like acute myeloid leukemia and myelodysplastic syndromes. Additionally, they are developing a CD45-antibody drug conjugate, undergoing investigational new drug application enabling studies, with potential applications as a single-agent therapy in autoimmune diseases and hematology-oncology transplants. MGTA-145 is in Phase II clinical trials for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta has established strategic collaborations with companies like AVROBIO, Inc. for the treatment of lysosomal storage disorders, and Beam Therapeutics, Inc. to explore the utility of MGTA-117 in conditioning patients with sickle cell disease and beta-thalassemia.
What Products and Services Does MGTA Offer?
- Develop medicines to improve stem cell transplants.
- Target blood cancers, genetic diseases, and autoimmune diseases.
- Develop MGTA-117, an anti-CD117 antibody in Phase I/II clinical trials.
- Develop CD45-antibody drug conjugate in investigational new drug application enabling studies.
- Advance MGTA-145 in Phase II clinical trials for autologous and allogeneic transplants.
- Develop E478, a cell therapy program for stem cell-based gene therapy and genome editing.
- Collaborate with AVROBIO for lysosomal storage disorders.
- Collaborate with Beam Therapeutics for sickle cell disease and beta-thalassemia.
How Does MGTA Make Money?
- Develop and license novel therapeutics for stem cell transplantation.
- Generate revenue through strategic collaborations and partnerships.
- Seek regulatory approval for drug candidates and commercialize approved therapies.
- Focus on research and development of innovative medicines.
What Industry Does MGTA Operate In?
Magenta Therapeutics operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy clinical trials, and regulatory hurdles. The stem cell transplant market is driven by advancements in cell and gene therapies, offering potential cures for previously untreatable diseases. Companies like SYRE: Spyre Therapeutics, Inc. are also active in the biotechnology space. The success of Magenta depends on its ability to navigate the complex regulatory landscape, secure funding, and demonstrate clinical efficacy. The biotechnology industry is experiencing growth driven by increasing demand for personalized medicine and innovative therapies.
Who Are MGTA's Key Customers?
- Patients with blood cancers, genetic diseases, and autoimmune disorders.
- Hospitals and transplant centers.
- Pharmaceutical companies through collaborations and licensing agreements.
How Magenta Therapeutics, Inc. Is Valued
Magenta Therapeutics, Inc. carries a market capitalization of $42.4M, placing it in the micro-cap category.
Company Profile
Magenta Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Stephen F. Mahoney MBA. MGTA has traded publicly since 2018.
Key Financial Metrics
Return on equity for Magenta Therapeutics, Inc. stands at -27.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.9%, showing how much profit it generates from its asset base. A current ratio of 29.25 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Magenta Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.71 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
The most recent 11 insider filings for Magenta Therapeutics, Inc. break down as 0 sales and 11 purchases. On net that is roughly 139K shares acquired (about $1.7M) — insiders putting money in tends to read as conviction.
MGTA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Magenta's future, indicating key stakeholders believe in the company's potential.
- Community sentiment has shifted positively as recent clinical trial updates have generated excitement around their therapies.
- Increased partnerships with research institutions have bolstered the company's credibility and visibility in the biotech space.
- The market is responding favorably to Magenta's innovative approaches, which align with growing trends in personalized medicine.
Bear Case
- Concerns remain about the pace of clinical trial progress, leading to skepticism regarding timely product launches.
- Recent social sentiment has shown mixed reactions, with some community members expressing doubts about the company's long-term viability.
- Increased competition in the biotech sector poses a risk, as new entrants may overshadow Magenta's advancements.
- Market perception has been cautious, with some investors wary of the inherent risks associated with biotech investments, particularly in early-stage companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MGTA Latest News
No recent news available for MGTA.
Leadership: Stephen F. Mahoney MBA
Chief Executive Officer
Stephen F. Mahoney is the Chief Executive Officer of Magenta Therapeutics, bringing extensive experience in the biotechnology and pharmaceutical industries. He holds an MBA and has a proven track record in leading and growing companies. Prior to joining Magenta, Mahoney held leadership positions at various biotech firms, focusing on strategic planning, business development, and commercialization. His expertise spans across multiple therapeutic areas, including oncology and immunology. He is responsible for overseeing Magenta's overall strategy and operations.
Track Record: Under Stephen Mahoney's leadership, Magenta Therapeutics has focused on advancing its pipeline of stem cell transplant therapies. He has overseen the progression of key drug candidates through clinical trials and has established strategic collaborations to expand the company's reach. Key milestones include advancing MGTA-117 into Phase I/II clinical trials and securing partnerships with AVROBIO and Beam Therapeutics. His focus is on driving innovation and shareholder value.
Magenta Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What happened to Magenta Therapeutics, Inc. (MGTA) stock?
Magenta Therapeutics, Inc. (MGTA) no longer trades on public markets. It was delisted in September 2023. The figures below are historical and are not a current quote.
Can I still buy MGTA shares?
No. MGTA stopped trading on public markets in September 2023, so the shares are not available through a broker. Anything you see quoted for MGTA elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MGTA stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Magenta Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Magenta Therapeutics, Inc. do?
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative medicines to improve stem cell transplantation outcomes. The company's pipeline includes novel antibody drug conjugates and cell therapy programs targeting blood cancers, genetic diseases, and autoimmune disorders.
What do analysts say about MGTA stock?
Analyst coverage of Magenta Therapeutics, Inc. is limited, reflecting its small market capitalization and clinical-stage status. Key valuation metrics are influenced by the potential success of its pipeline and the inherent risks associated with biotechnology drug development. Growth considerations center on the advancement of MGTA-117, CD45-antibody drug conjugate, and MGTA-145 through clinical trials.
What are the main risks for MGTA?
The main risks for Magenta Therapeutics, Inc. include clinical trial failures, regulatory setbacks, and competition from established pharmaceutical companies. As a clinical-stage company, Magenta faces significant uncertainty regarding the success of its drug candidates. Regulatory hurdles and potential delays in the approval process pose additional risks. The company's reliance on future funding and market conditions also presents financial risks.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Analyst opinions may vary.